SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-207441
Filing Date
2023-08-09
Accepted
2023-08-09 16:40:02
Documents
18
Period of Report
2023-08-08
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K d529219d8k.htm   iXBRL 8-K 31547
2 EX-1.1 d529219dex11.htm EX-1.1 242626
3 EX-4.1 d529219dex41.htm EX-4.1 61610
4 EX-5.1 d529219dex51.htm EX-5.1 14287
5 EX-99.1 d529219dex991.htm EX-99.1 6928
6 EX-99.2 d529219dex992.htm EX-99.2 6943
10 GRAPHIC g529219g0809115036306.jpg GRAPHIC 2233
  Complete submission text file 0001193125-23-207441.txt   582420

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA mrtx-20230808.xsd EX-101.SCH 2836
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE mrtx-20230808_lab.xml EX-101.LAB 17236
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mrtx-20230808_pre.xml EX-101.PRE 10803
12 EXTRACTED XBRL INSTANCE DOCUMENT d529219d8k_htm.xml XML 3199
Mailing Address 3545 CRAY COURT SAN DIEGO CA 92121
Business Address 3545 CRAY COURT SAN DIEGO CA 92121 858-332-3410
Mirati Therapeutics, Inc. (Filer) CIK: 0001576263 (see all company filings)

IRS No.: 462693615 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35921 | Film No.: 231155838
SIC: 2834 Pharmaceutical Preparations